FDA Approves First At-Home Brain Stimulation Device for Depression

December 12, 2025

WASHINGTON, D.C. — In a landmark decision that could reshape how mental health treatment is delivered in the United States, the Food and Drug Administration (FDA) on Thursday approved the first at-home brain stimulation device for the treatment of major depressive disorder (MDD). The device, a headset developed by Flow Neuroscience, utilizes transcranial direct current stimulation (tDCS) to target brain activity associated with depression, offering a new, non-drug option for millions of Americans.

The approval marks a significant shift in psychiatric care, moving a technology previously confined to specialized clinics directly into patients’ living rooms. The device, known as the Flow FL-100, is indicated for use by adults with moderate to severe depression and can be used either as a standalone treatment or alongside existing antidepressant medications.

A New Era of Home-Based Care

The FDA’s authorization comes as the U.S. continues to grapple with a mental health crisis and a shortage of mental health professionals. While traditional antidepressants are effective for many, approximately one-third of patients do not respond adequately to medication or cannot tolerate the side effects, which can include weight gain, insomnia, and sexual dysfunction.

“We’re on a mission to make effective, affordable non-drug treatment available to the millions of Americans suffering from depression,” said Erin Lee, CEO of Flow Neuroscience. “Flow’s FDA approval is a watershed moment for the treatment of depression: the first step in moving from pharmaceutical treatments to tech-based therapies with minimal side effects.”

The device works by delivering a weak electrical current to the dorsolateral prefrontal cortex (DLPFC), an area of the brain involved in cognitive control and emotional regulation. In people with depression, this region often shows reduced activity. The headset is designed to gently stimulate the area to restore normal activity patterns, a mechanism similar to Transcranial Magnetic Stimulation (TMS), which is typically performed in a clinical setting.

Clinical Evidence and Efficacy

The FDA’s decision was supported by data from a randomized, double-blind, placebo-controlled trial involving 174 adult participants with major depressive disorder. Patients used the device for 30-minute sessions—five times a week for the first three weeks, followed by three times a week for the next seven weeks.

The study, results of which were published in Nature Medicine, highlighted several key findings:

• High Remission Rates: Approximately 54% of patients using the active device achieved remission (complete disappearance of symptoms) after 10 weeks, compared to roughly 23% in the placebo (sham) group.

• Response Rate: The treatment group showed a significantly higher clinical response rate (58.3%) compared to the sham group (37.8%).

• Speed of Relief: Many users reported noticeable symptom improvement within just three weeks of starting treatment.

Importantly, the trial demonstrated a strong safety profile. Unlike systemic medications, the device’s side effects were localized and mild, primarily consisting of skin irritation, redness at the electr³ode site, and occasional headaches. No serious adverse events were reported.

Expert Perspectives

The approval has been met with cautious optimism by the psychiatric community, who see it as a vital tool for bridging the gap between medication and intensive clinical procedures.

Dr. Daniel Blumberger, a senior scientist at the Centre for Addiction and Mental Health in Toronto, who was not involved in the device’s development but advises on similar technologies, called the approval a significant milestone.

“This opens up a new era of treatment for depression,” Blumberger noted. “While other electric stimulation devices have been marketed, the evidence for Flow’s headset is much more robust. It offers a scalable way to expand access to effective depression care for patients who might otherwise face barriers to in-clinic treatments like TMS.”

However, experts also advise managing expectations. Dr. Kultar Garcha, Flow’s Chief Medical Officer, emphasized that while the device is a powerful tool, it is part of a broader treatment landscape. “Among our real-world users, 77% see improvements in as little as three weeks,” Garcha stated. “But it is crucial that patients work with healthcare providers to determine if this is the right approach for their specific profile.”

Practical Implications for Patients

For patients, this approval means access to a new modality of treatment without the logistical burden of daily clinic visits.

• Availability: The device is expected to launch in the U.S. market in the second quarter of 2026.

• Access: It will be available by prescription only. Patients will need to consult with a psychiatrist or primary care provider to obtain it.

• Usage: The treatment is controlled via a smartphone app, which guides users through the sessions and tracks progress.

• Cost: While final U.S. pricing is still being determined, the company has indicated a price point around $500, or a potential subscription model. Discussions with insurance providers regarding coverage are ongoing.

Limitations and Future Outlook

While the data is promising, the FDA noted that the clinical benefit, while statistically significant, was “modest” for some subgroups. Additionally, the long-term durability of the effect beyond the 10-week trial period is still being studied, though real-world data from Europe (where the device has been available since 2019) suggests sustained benefits for many users.

The approval also raises questions about adherence; unlike a pill, the treatment requires a time commitment of 30 minutes several times a week. However, the ability to use the device while performing other passive tasks at home may mitigate this burden.

As the mental health field continues to embrace digital therapeutics and home-based neuromodulation, the Flow headset represents a tangible step toward personalized, accessible care. For the millions of Americans navigating the darkness of depression, this device may offer a new, much-needed light.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. FDA Announcement: U.S. Food and Drug Administration. (2025, December 11). “FDA Approves First At-Home Transcranial Direct Current Stimulation Device for Depression.”

2. Company Press Release: Flow Neuroscience. (2025, December 11). “Flow Neuroscience receives FDA approval for first at-home depression treatment device.”